Tina Bhutani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1526778/publications.pdf

Version: 2024-02-01

100 papers

3,578 citations

236925 25 h-index 56 g-index

112 all docs

112 docs citations

112 times ranked $\begin{array}{c} 6001 \\ \text{citing authors} \end{array}$

#	Article	IF	CITATIONS
1	Racial disparities in clinical trials of biologic treatments for psoriatic arthritis. Journal of the American Academy of Dermatology, 2022, 87, 910-912.	1.2	5
2	A cross-sectional study of ethnoracial representation in pediatric plaque psoriasis clinical trials. Journal of the American Academy of Dermatology, 2022, 86, 442-444.	1.2	1
3	Evaluation of a Case Series of Patients With Generalized Pustular Psoriasis in the United States. JAMA Dermatology, 2022, 158, 73.	4.1	17
4	Combined Single Cell Transcriptome and Surface Epitope Profiling Identifies Potential Biomarkers of Psoriatic Arthritis and Facilitates Diagnosis via Machine Learning. Frontiers in Immunology, 2022, 13, 835760.	4.8	11
5	Sleep, Immunological Memory, and Inflammatory Skin Disease. Dermatology, 2021, 237, 1035-1038.	2.1	5
6	Biologic Treatment of 4 HIV-Positive Patients: A Case Series and Literature Review. Journal of Psoriasis and Psoriatic Arthritis, 2021, 6, 19-26.	0.7	15
7	Single-cell RNA sequencing of psoriatic skin identifies pathogenic Tc17 cell subsets and reveals distinctions between CD8+ T cells in autoimmunity and cancer. Journal of Allergy and Clinical Immunology, 2021, 147, 2370-2380.	2.9	77
8	Sleep and the Gut Microbiome in Psoriasis: Clinical Implications for Disease Progression and the Development of Cardiometabolic Comorbidities. Journal of Psoriasis and Psoriatic Arthritis, 2021, 6, 27-37.	0.7	4
9	Advancements in Biologic Therapy for Psoriasis: the IL-23 Inhibitors. Current Dermatology Reports, 2021, 10, 6-15.	2.1	1
10	Halobetasol Propionate and Tazarotene Combination Lotion 0.01%/0.045% for Psoriasis. Current Dermatology Reports, 2021, 10, 21-25.	2.1	0
11	Phototherapy for Psoriasis: New Research and Insights. Current Dermatology Reports, 2021, 10, 16-20.	2.1	2
12	A common treatment for a rare condition: Narrowbandâ€Ultraviolet B (NBâ€UVB) phototherapy for the treatment of a recalcitrant acquired port wine stain. Photodermatology Photoimmunology and Photomedicine, 2021, 37, 293-295.	1.5	0
13	Biologic Treatments of Psoriasis: An Update for the Clinician. Biologics: Targets and Therapy, 2021, Volume 15, 39-51.	3.2	40
14	Genital and Inverse/Intertriginous Psoriasis: An Updated Review of Therapies and Recommendations for Practical Management. Dermatology and Therapy, 2021, 11, 833-844.	3.0	10
15	Scalp Psoriasis: A Literature Review of Effective Therapies and Updated Recommendations for Practical Management. Dermatology and Therapy, 2021, 11, 769-797.	3.0	23
16	Nail Psoriasis: A Review of Effective Therapies and Recommendations for Management. Dermatology and Therapy, 2021, 11, 799-831.	3.0	12
17	The future of personalized medicine in psoriasis. Dermatological Reviews, 2021, 2, 282.	0.5	О
18	Inpatient Management of Psoriasis: A Current Perspective and Update for Clinicians. Current Dermatology Reports, 2021, 10, 205-221.	2.1	1

#	Article	IF	Citations
19	Perspectives on the Future Development of Mobile Applications for Dermatology Clinical Research. Dermatology and Therapy, 2021, 11, 1451-1456.	3.0	5
20	Psoriasis and Cardiometabolic Comorbidities: An Evaluation of the Impact of Systemic Treatments in Randomized Clinical Trials. Dermatology and Therapy, 2021, 11, 1497-1520.	3.0	5
21	Biologics update: ILâ€23 inhibitors. Dermatological Reviews, 2021, 2, 276.	0.5	O
22	Dupilumab-Induced Facial Flushing After Alcohol Consumption., 2021, 108, 106-107.		2
23	Atypical Presentation of Pityriasis Rubra Pilaris: Challenges in Diagnosis and Management. , 2021, 108, E33-E35.		0
24	The Role of IL-17 Cytokines in Psoriasis. ImmunoTargets and Therapy, 2021, Volume 10, 409-418.	5.8	24
25	Implementation of an Ultraviolet Phototherapy Service at a National Referral Hospital in Western Kenya: Reflections on Challenges and Lessons Learned. Dermatology and Therapy, 2020, 10, 107-117.	3.0	0
26	Beyond the Booth. Dermatologic Clinics, 2020, 38, 157-163.	1.7	7
27	Evaluation of a Genetic Risk Score for Diagnosis of Psoriatic Arthritis. Journal of Psoriasis and Psoriatic Arthritis, 2020, 5, 61-67.	0.7	4
28	Novel Coronavirus Disease (COVID-19) and Biologic Therapy for Psoriasis: Successful Recovery in Two Patients After Infection with Severe Acute Respiratory Syndrome CoronavirusÂ2 (SARS-CoV-2). Dermatology and Therapy, 2020, 10, 881-885.	3.0	12
29	Lymphomatoid papulosis successfully managed with excimer laser maintenance therapy. JAAD Case Reports, 2020, 6, 495-497.	0.8	2
30	<p>Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults</p> . Clinical, Cosmetic and Investigational Dermatology, 2020, Volume 13, 391-398.	1.8	0
31	Brodalumab for Treatment-Resistant Psoriasis: Case Reports and Safety Update. Journal of Psoriasis and Psoriatic Arthritis, 2020, 5, 82-85.	0.7	1
32	Psoriasis Vulgaris Successfully Treated with Goeckerman Treatment at Home: A Patient and Physician's Experience. Dermatology and Therapy, 2020, 10, 329-338.	3.0	1
33	Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times. Dermatology and Therapy, 2020, 10, 339-349.	3.0	37
34	Review of European registries for psoriasis. Journal of Dermatological Treatment, 2019, 30, 227-236.	2.2	10
35	Dupilumab for the treatment of severe photodermatitis. JAAD Case Reports, 2019, 5, 614-616.	0.8	5
36	<p>Home phototherapy for patients with vitiligo: challenges and solutions</p> . Clinical, Cosmetic and Investigational Dermatology, 2019, Volume 12, 451-459.	1.8	8

#	Article	IF	Citations
37	Dupilumab in patients with chronic hepatitis B on concomitant entecavir. JAAD Case Reports, 2019, 5, 624-626.	0.8	14
38	Emerging Methods to Objectively Assess Pruritus in Atopic Dermatitis. Dermatology and Therapy, 2019, 9, 407-420.	3.0	17
39	Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis Design, Development and Therapy, 2019, Volume 13, 1993-2000.	4.3	10
40	Chronic erythema nodosum with koebnerization to plaque psoriasis. International Journal of Women's Dermatology, 2019, 5, 387-388.	2.0	0
41	Palmoplantar Pustulosis in Electronic Cigarette Users: A Potential for Concern. Dermatology, 2019, 235, 525-526.	2.1	1
42	Anti IL-17 in psoriasis. Expert Review of Clinical Immunology, 2019, 15, 1185-1194.	3.0	61
43	<p>Acrodermatitis continua of Hallopeau: clinical perspectives</p> . Psoriasis: Targets and Therapy, 2019, Volume 9, 65-72.	2.2	34
44	<p>Diagnosis and screening of patients with generalized pustular psoriasis</p> . Psoriasis: Targets and Therapy, 2019, Volume 9, 37-42.	2.2	31
45	Factors Influencing Sleep Difficulty and Sleep Quantity in the Citizen Pscientist Psoriatic Cohort. Dermatology and Therapy, 2019, 9, 511-523.	3.0	20
46	A20 and ABIN1 Suppression of a Keratinocyte Inflammatory Program with a Shared Single-Cell Expression Signature in Diverse Human Rashes. Journal of Investigative Dermatology, 2019, 139, 1264-1273.	0.7	16
47	A review of dupilumab in the treatment of atopic diseases. Human Vaccines and Immunotherapeutics, 2019, 15, 2129-2139.	3.3	53
48	The impact of pediatric atopic dermatitis on families: A review. Pediatric Dermatology, 2019, 36, 66-71.	0.9	66
49	Dupilumab Treatment for Generalized Prurigo Nodularis. JAMA Dermatology, 2019, 155, 118.	4.1	60
50	Pharmacy costs of systemic medications for hidradenitis suppurativa in the United States. Journal of Dermatological Treatment, 2019, 30, 519-521.	2.2	6
51	Pharmacy costs of specialty medications for plaque psoriasis in the United States. Journal of the American Academy of Dermatology, 2019, 80, 274-275.	1.2	3
52	Guselkumab for the treatment of moderate-to-severe plaque psoriasis. Expert Review of Clinical Pharmacology, 2018, 11, 333-344.	3.1	8
53	Vagus Nerve Stimulation. Journal of Psoriasis and Psoriatic Arthritis, 2018, 3, 54-58.	0.7	1
54	Neuromodulation in Inflammatory Skin Disease. Dermatology and Therapy, 2018, 8, 1-4.	3.0	3

#	Article	IF	CITATIONS
55	Review of IL-17 inhibitors for psoriasis. Journal of Dermatological Treatment, 2018, 29, 347-352.	2.2	21
56	A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis. Journal of Dermatological Treatment, 2018, 29, 467-474.	2.2	6
57	Review of the mechanism of action of coal tar in psoriasis. Journal of Dermatological Treatment, 2018, 29, 230-232.	2.2	27
58	Recent Developments in Atopic Dermatitis. Pediatrics, 2018, 142, .	2.1	23
59	IL-23 Inhibitors for Psoriasis. Current Dermatology Reports, 2018, 7, 119-124.	2.1	3
60	Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies. Cutis, 2018, 101, 38;42;56.	0.3	12
61	Do psoriasis patients engage in vigorous physical activity?. Cutis, 2018, 101, 198-200.	0.3	2
62	Emerging therapies in psoriasis: a systematic review. Cutis, 2018, 101, 5-9.	0.3	15
63	Psoriasis risk factors and triggers. Cutis, 2018, 102, 18-20.	0.3	31
64	Warfarin-Associated Nonuremic Calciphylaxis. JAMA Dermatology, 2017, 153, 309.	4.1	74
65	Influence of diet on the gut microbiome and implications for human health. Journal of Translational Medicine, 2017, 15, 73.	4.4	1,714
66	Beyond monotherapy: a systematic review on creative strategies in topical therapy of psoriasis. Journal of Dermatological Treatment, 2017, 28, 702-708.	2.2	10
67	Considerations on biologic agents in psoriasis with the new pregnancy lactation labeling rule. International Journal of Women's Dermatology, 2017, 3, S67-S69.	2.0	2
68	Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities. JAAD Case Reports, 2017, 3, 495-497.	0.8	21
69	Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis. Human Vaccines and Immunotherapeutics, 2017, 13, 2247-2259.	3.3	87
70	Frequency and Management of Sleep Disturbance in Adults with Atopic Dermatitis: A Systematic Review. Dermatology and Therapy, 2017, 7, 349-364.	3.0	66
71	Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib. Journal of the American Academy of Dermatology, 2017, 77, 713-718.	1.2	52
72	Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials. Dermatology and Therapy, 2017, 7, 281-292.	3.0	49

#	Article	IF	Citations
73	Eczema as an adverse effect of anti-TNFα therapy in psoriasis and other Th1-mediated diseases: a review. Journal of Dermatological Treatment, 2017, 28, 237-241.	2.2	43
74	Obsessive-compulsive skin disorders: a novel classification based on degree of insight. Journal of Dermatological Treatment, 2017, 28, 342-346.	2.2	22
75	Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis. Psoriasis: Targets and Therapy, 2017, Volume 7, 65-72.	2.2	4
76	Improvement in Quality of Life in Patients with Moderate to Severe Psoriasis Treated with Adalimumab or Ustekinumab. Journal of Psoriasis and Psoriatic Arthritis, 2016, 1, 161-166.	0.7	0
77	Recent advances in phototherapy for psoriasis. F1000Research, 2016, 5, 1684.	1.6	19
78	Combining biologic and phototherapy treatments for psoriasis: safety, efficacy, and patient acceptability. Psoriasis: Targets and Therapy, 2016, Volume 6, 105-111.	2.2	11
79	Article Commentary: Explaining the Shift to Value-Based Reimbursement in the Setting of Dermatology and Psoriasis. Journal of Psoriasis and Psoriatic Arthritis, 2016, 2, 5-8.	0.7	0
80	Excimer laser for the treatment of psoriasis: safety, efficacy, and patient acceptability. Psoriasis: Targets and Therapy, 2016, Volume 6, 165-173.	2.2	12
81	Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials. Dermatology and Therapy, 2016, 6, 111-124.	3.0	82
82	The Patient's Guide to Psoriasis Treatment. Part 1: UVB Phototherapy. Dermatology and Therapy, 2016, 6, 307-313.	3.0	27
83	The Patient's Guide to Psoriasis Treatment. Part 4: Goeckerman Therapy. Dermatology and Therapy, 2016, 6, 333-339.	3.0	10
84	The Patient's Guide to Psoriasis Treatment. Part 2: PUVA Phototherapy. Dermatology and Therapy, 2016, 6, 315-324.	3.0	18
85	The Patient's Guide to Psoriasis Treatment. Part 3: Biologic Injectables. Dermatology and Therapy, 2016, 6, 325-331.	3.0	6
86	Successful use of a modified Goeckerman regimen in the treatment of chronic severe atopic dermatitis: A prospective pilot study. Journal of the American Academy of Dermatology, 2016, 75, 1068-1071.	1.2	4
87	The role of IL-17 in vitiligo: A review. Autoimmunity Reviews, 2016, 15, 397-404.	5.8	92
88	lxekizumab for the Treatment of Psoriasis: A Review of Phase III Trials. Dermatology and Therapy, 2016, 6, 25-37.	3.0	62
89	Demyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: A review. Journal of Dermatological Treatment, 2016, 27, 406-413.	2.2	26
90	Considerations on biologic agents in psoriasis with the new pregnancy lactation labeling rule. International Journal of Women's Dermatology, 2016, 2, 62-64.	2.0	4

#	Article	IF	CITATION
91	The Role of the Nervous System in the Pathophysiology of Psoriasis: A Review of Cases of Psoriasis Remission or Improvement Following Denervation Injury. American Journal of Clinical Dermatology, 2016, 17, 257-263.	6.7	47
92	Sweet heart: A case of pregnancy-associated acute febrile neutrophilic dermatosis with myopericarditis. JAAD Case Reports, 2015 , 1 , $12-14$.	0.8	5
93	A prospective, interventional assessment of psoriasis quality of life using a nonskin-specific validated instrument that allows comparison with other major medical conditions. Journal of the American Academy of Dermatology, 2013, 69, e79-e88.	1.2	30
94	Intralesional injections of alefacept may predict systemic response to intramuscular alefacept: results from a pilot study. Journal of Dermatological Treatment, 2013, 24, 348-350.	2.2	1
95	Access to Health Care in Patients With Psoriasis and Psoriatic Arthritis. JAMA Dermatology, 2013, 149, 717.	4.1	41
96	Efficacy of clobetasol spray: Factors beyond patient compliance. Journal of Dermatological Treatment, 2012, 23, 11-15.	2.2	7
97	Management of Pediatric Psoriasis. Pediatric Annals, 2012, 41, e1-7.	0.8	27
98	A Clinical Study Comparing the Efficacy of Halobetasol Propionate 0.05% Ointment Once Daily versus Twice Daily in Combination with Ammonium Lactate Lotion in the Treatment of Stable Plaque Psoriasis. Psoriasis Forum, 2011, 17a, 2-8.	0.1	1
99	A Practical Approach to Home UVB Phototherapy for the Treatment of Generalized Psoriasis. Practical Dermatology, 2010, 7, 31-35.	0.0	7
100	Common sources of skin care education: a cross-sectional study. International Journal of Dermatology, 2009, 48, 506-512.	1.0	4